Compare RL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RL | INSM |
|---|---|---|
| Founded | 1967 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 23.0B |
| IPO Year | 1997 | 2000 |
| Metric | RL | INSM |
|---|---|---|
| Price | $379.94 | $104.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 24 |
| Target Price | ★ $406.75 | $201.17 |
| AVG Volume (30 Days) | 522.0K | ★ 2.3M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ 30.15 | N/A |
| EPS | ★ 15.11 | N/A |
| Revenue | ★ $8,114,500,000.00 | N/A |
| Revenue This Year | $15.92 | $182.31 |
| Revenue Next Year | $5.80 | $65.19 |
| P/E Ratio | $24.72 | ★ N/A |
| Revenue Growth | ★ 14.63 | N/A |
| 52 Week Low | $273.04 | $90.39 |
| 52 Week High | $421.60 | $212.75 |
| Indicator | RL | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 46.76 |
| Support Level | $366.66 | $105.07 |
| Resistance Level | $383.30 | $119.54 |
| Average True Range (ATR) | 12.76 | 4.12 |
| MACD | -1.57 | -0.48 |
| Stochastic Oscillator | 38.21 | 9.68 |
Founded by designer Ralph Lauren (current executive chairman and chief creative officer) in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.